ProteoGenix

What ProteoGenix does

ProteoGenix is a privately-held contract research organization (CRO) founded in 2003 and headquartered in Schiltigheim, France, with a US subsidiary (ProteoGenix Inc.) in Morrisville, North Carolina. The company specializes in custom antibody discovery, engineering, and production, serving pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs/CDMOs), academic and cancer research institutions, diagnostics developers, and animal health companies worldwide. Its customer base spans Singapore (National Cancer Centre), the UK (Birmingham University), the United States (Brown University), Spain (Telum Therapeutics), and Israel (Canopy Immuno-Therapeutics), with 70+ antibodies produced through its services currently advancing through clinical trials.

The company operates a platform-plus-services model built around proprietary wet-lab and AI capabilities. Core technology platforms include AIxplore® (AI-driven antibody design for humanization, affinity maturation, and developability optimization), XtenCHO™ Race (CHO transient expression system producing multi-gram protein in 8 days), RocketAbs™ (immunization platform up to 50% faster than competitors), and a 368-donor naïve human antibody library complemented by LibAb-SFDog™, the first naïve dog antibody library on the market. Service offerings span the full antibody value chain: gene synthesis, peptide synthesis, custom antibody production (phage display, hybridoma, single B cell screening), antibody engineering (bispecifics, ADCs, humanization), recombinant protein production across five expression systems (E. coli, B. subtilis, yeast, insect, mammalian), stable cell line development, and epitope mapping. The company also maintains a 30,000+ SKU bioreagent catalog sold via e-commerce.

ProteoGenix operates a dual go-to-market motion: PhD-level account managers handle enterprise custom-service projects (48-hour quotes, 2-24 hour callbacks, multi-year contracts, no-win-no-fee guarantees on certain services, royalty-free IP), while a self-service e-commerce storefront serves the long tail of catalog customers with instant ordering, loyalty programs, and first-order discounts. The company employs approximately 160 collaborators globally (around 40% with PhDs) and holds ISO 9001, ISO 14001, and French CIR R&D tax credit (2023-2027) certifications. The company is founder-controlled with no disclosed institutional investors.

Name

ProteoGenix

Legal name

ProteoGenix SAS

Website

https://proteogenix.science

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

ProteoGenix is a privately-held contract research organization specializing in custom antibody discovery, engineering, and production services for biopharma, diagnostics, research, and animal health clients worldwide, leveraging proprietary AI design and high-performance expression platforms.

Ownership category

akta.pro rank

Product category

Antibody Discovery & Biologics Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Custom antibody production
• Antibody discovery services
• Recombinant protein expression
• Peptide synthesis services
• Gene synthesis services

Headquarters

HQ city

Costa Mesa

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Custom Antibody Production Services: Comprehensive antibody development services including discovery, engineering, humanization, and characterization. Revenue generated through project-based fees with no win/no fee guarantees for certain services. Includes hybridoma technology, phage display, and single B cell screening.
2. Recombinant Protein Production: Protein expression across multiple systems (E. coli, B. subtilis, yeast, insect cells, mammalian cells) with scalable production from mg to kg-scale. High-throughput screening services available.
3. Peptide Synthesis: Custom peptide synthesis from 1 to thousand peptides, ranging from mg to gram-scale. Starting at €1.66/AA in EU or $2.12/AA in US markets.
4. Gene Synthesis: Custom gene synthesis with 100% sequence guarantee, starting from €0.14€/bp or $0.18/bp.
5. Bioreagents Products: Off-the-shelf products including 6,000+ primary antibodies, 6,000+ recombinant proteins, ELISA assay kits, and cell separation media. 30,000+ total catalog products with 25% first-order discount available.
6. Custom Cell Line Development: Stable cell line development services for gram to kg-scale protein production. Services include royalty-free licensing upon full payment for custom deliverables.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

ProteoGenix is a contract research organization (CRO) that provides end-to-end custom antibody discovery, engineering, and production services, complemented by recombinant protein expression, peptide synthesis, gene synthesis, and stable cell line development. The company combines proprietary wet-lab platforms (phage display, hybridoma, CHO expression) with its AIxplore® AI-driven antibody design platform to deliver integrated antibody solutions from gene to biotherapeutics. It also distributes a catalog of 30,000+ bioreagents (primary antibodies, recombinant proteins, ELISA kits, cell separation media) through its own e-commerce shop.

Product overview

ProteoGenix is a science-driven CRO (Contract Research Organization) specializing in integrated antibody solutions from gene to biotherapeutics and diagnostics. The company operates a platform-plus-services model combining proprietary technologies with comprehensive service offerings. The core technology stack includes AIxplore® (AI-powered antibody design), XtenCHO™ Race (high-performance mammalian expression system), RocketAbs™ (accelerated immunization platform), and proprietary antibody libraries including LibAb-SF-Dog™ (first dog antibody library). Services span the entire development pipeline: custom antibody production (phage display, hybridoma, recombinant), antibody engineering (humanization, bispecifics, ADCs), protein expression (5 expression systems), peptide synthesis, gene synthesis, and cell line development. The company also maintains a catalog of 30,000+ bioreagents including primary antibodies, recombinant proteins, and ELISA kits available through its online shop. Founded in 2003, ProteoGenix serves pharmaceutical, biotech, CMO/CDMO clients across therapeutics, diagnostics, and animal health sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Antibody Production Services
• Antibody Discovery Services
• Antibody Engineering Services
• Recombinant Antibody Production Services
• VHH Production
• Animal Health Antibodies
• Epitope Mapping Services
• High-Throughput Antibody Production
• Custom Protein Expression Services
• Custom Cell Line Development
• Custom Peptide Synthesis
• Custom Gene Synthesis
• Primary Antibodies (Catalog)
• Recombinant Proteins (Catalog)
• ELISA Assay Kits
• Nycodenz AG®
• AIxplore® AI Antibody Design Service
• XtenCHO™ Race Expression System (incl. Starter Kit)

Quantifiable outcome

• High-affinity antibodies delivered in 1 month with 10⁻⁹ to 10⁻¹² M binding affinity
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Synbio Technologies: Gene synthesis, peptide synthesis, and protein expression CRO serving life sciences research. Directly comparable to ProteoGenix's gene synthesis, peptide synthesis, and custom protein expression services.
• Eurogentec (Kaneka): Belgian CRO/CDMO (now part of Kaneka) offering custom antibody production, oligonucleotide synthesis, and peptide services. Highly comparable in therapeutic antibody production and European CRO positioning.
• Rockland Immunochemicals: US-based antibody manufacturer offering custom polyclonal and monoclonal antibody production, conjugation, and assay development. Similar size and service mix to ProteoGenix's catalog and custom antibody businesses.
• Medix Biochemica: Finnish antibody company specializing in monoclonal antibody development and IVD-grade reagent manufacturing. Directly comparable in diagnostic and research antibody production.
• GenScript: Global CRO offering custom antibody services, gene synthesis, peptide synthesis, and protein production — a direct head-to-head competitor across nearly every ProteoGenix service line, with significantly larger scale.
• Sino Biological: Recombinant protein and antibody CRO/CDMO serving research and therapeutic customers with catalog and custom offerings. Directly comparable in antibody discovery, recombinant production, and diagnostic reagent business.
• Absolute Antibody: UK-based recombinant antibody CRO offering custom antibody engineering, production, and sequencing services. Closely comparable in scale and therapeutic antibody focus.

Broad incumbents

• Charles River Laboratories: Global CRO providing antibody discovery and production services as part of its broader preclinical and manufacturing portfolio. Competes with ProteoGenix in therapeutic antibody services but serves a much wider customer base.
• Abcam: Major antibody reagents supplier (now part of Danaher) with a vast catalog of validated antibodies for research and diagnostics. Overlaps with ProteoGenix's catalog bioreagent and custom diagnostic antibody offerings.
• Bio-Techne (R&D Systems): Large life sciences tools company with extensive antibody catalog (R&D Systems), protein reagents, and ELISA kits. Competes with ProteoGenix's catalog bioreagent business and offers custom services through its ProteinSimple and ExoDx brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ProteoG
• Facebookfacebook.com/ProteoGenix
• LinkedInlinkedin.com/company/proteogenix

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProteoGenix